IOTOX Algorithm

Immuno-Oncology Toxicity (IOTOX) Evaluation and Management Algorithms

Immunotherapies have become essential in treating advanced malignancies. However, immunotherapies can attack healthy cells, leading to toxicities or side effects.

To address how to best treat patients with these toxicities, the Internal Medicine division has collaborated with the Cancer Medicine division, as well as other divisions at MD Anderson, to create the Immuno-Oncology Toxicity (IOTOX) Leaders Group. ​​​​​​

Clinical management algorithms depict best practices for evaluating, diagnosing, and treating specific conditions that arise during the course of cancer treatment. These algorithms are not intended to replace the independent medical judgment of the physician in the context of individual clinical circumstances to determine a patient's care.